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Background: Overweight and obesity among young, adult women are increasing problems in Sweden as in many
other countries. The postpartum period may be a good opportunity to improve eating habits and lose weight in a
sustainable manner. The aim was to make a cost-utility analysis of a dietary behavior modification treatment
alongside usual care, compared to usual care alone, among lactating overweight and obese women.
Methods: This study was a cost-utility analysis based on a randomized controlled and longitudinal clinical diet
intervention. Between 2007-2010, 68 women living in Sweden were, after baseline measurement at 8-12 weeks
postpartum, randomly assigned to a 12-week dietary behavior modification treatment or control group. Inclusion
criteria were: self-reported pre-pregnancy body mass index (BMI) 25-35 kg/m2, non-smoker, singleton term delivery,
birth weight > 2500 g, intention to breastfeed for 6 mo and no diseases (mother and child). The women in the
intervention group received 1.5 hour of individual counseling at study start and 1 hour at follow-up home visits
after 6 weeks of intervention, with support through cell phone text messages every two wk. Dietary intervention
aimed to reduce dietary intake by 500 kcal/day. The control group received usual care. Weight results have
previously been reported. Here we report on analyses carried out during 2012-2013 of cost per quality adjusted life
years (QALY), based on the changes in quality of life measured by EQ-5D-3 L and SF-6D. Likelihood of
cost-effectiveness was calculated using Net Monetary Benefit method.
Results: Based on conservative assumptions of no remaining effect after 1 year follow-up, the diet intervention was
cost-effective. Costs per gained QALY were 8 643 – 9 758 USD. The likelihood for cost-effectiveness, considering a
willingness to pay 50 000 USD for a QALY, was 87–93%.
Conclusions: The diet intervention is cost-effective.
Trial registration: ClinicalTrials.gov Identifier: NCT01343238 Registered April 27, 2011.
The regional ethics committee in Gothenburg, Sweden, approved the study on November 15, 2006.
Keywords: Diet, Intervention, Obesity, Lactation, Cost-effectiveness, SwedenBackground
Overweight and obesity among young, adult women are
increasing problems in Sweden as in many other countries
[1,2], and pregnancy is associated with persistent weight
gain [3-5]. Pre-pregnancy overweight and obesity, and ex-
cessive gestational weight gain are risk factors for high
postpartum weight retention [6], hence exacerbating a* Correspondence: lars.hagberg@orebroll.se
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stated.woman’s initial condition with each pregnancy. According
to a meta-analysis of long-term weight loss in adults in
general, approximately half of the weight loss achieved in
successful weight loss programs was regained when the
first year after treatment ended [7]. Considering the in-
creased energy requirements of lactation [8,9] as well as
new routines and new habits in relation to the caring of
the newborn, the postpartum period may be a good op-
portunity to improve eating habits and lose weight in a
more sustainable manner.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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of a 12-week dietary modification program and a 9-month
follow-up period, among women who were overweight
or obese prior to pregnancy. The study showed signifi-
cant and clinically relevant results, with a reduction of
2.7 BMI units in the dietary behavior modification treat-
ment group compared to a reduction of 0.3 BMI units
in the usual care control group (p < 0,001) [10]. The
weight loss in the treatment group was sustained, and
even increased, at the 1-year follow-up. The results on
body weight and body composition have been reported
previously together with detailed descriptions of inter-
vention protocols [10]. However, the cost-effectiveness
of the program is unknown.
The aim of this study was to make a cost-utility analysis
of a dietary behavior modification treatment, compared to
usual care, among lactating overweight and obese women.
Methods
Study participants
Between 2007 and 2010, 76 women were recruited to the
study from 15 maternity clinics in Gothenburg, Sweden.
Inclusion criteria were: self-reported BMI 25-35 kg/m2 be-
fore pregnancy, non-smoker, singleton term delivery,
intention to breastfeed for 6 months, providing less than
20% of the child’s energy intake as a supplementary food,
birth weight > 2 500 g, and no known disease in mother or
child. Women with mild allergies and stable, medicated
hypothyroidism were eligible. The regional ethics commit-
tee in Gothenburg, Sweden, approved the study. All par-
ticipants provided written informed consent.
Study design
Baseline measurements were made 8-12 weeks after deliv-
ery. Out of the 76 recruited women, 68 women were, after
baseline measurement, randomly assigned to either the
dietary behavior modification treatment or the control
group (Figure 1). Half the participants in each group re-
ceived physical exercise intervention support consisting of a
moderate goal of 8 000 steps per day, within a classical 2×2
factorial design. However, we have previously determined
that the physical exercise intervention had no significant ef-
fect on daily step-count, total energy expenditure, body
weight or body composition at either time point [10].
Hence, in the current cost-effectiveness evaluation we have
compared those who received the diet intervention with
those who did not receive the diet intervention.
Measurements at baseline, 12 weeks and 1 year are de-
scribed in detail elsewhere [10]. The women were con-
tacted 6 months after the end of the 12-week intervention
and asked about medical conditions and whether they still
wanted to participate in the 1-year follow-up. Women
who became pregnant during the first 8 months of follow-
up were excluded from follow-up measurements. Womenwho were less than 1 month pregnant at the time of
follow-up measurements were kept in the study, because
only minimal changes in body weight are likely to have oc-
curred due to pregnancy at that stage [8].
Intervention
The women in the intervention group received 1.5 hours
of individual counseling at the start of the intervention
and 1 hour at follow-up home visits after 6 weeks of
intervention. Between visits, the women were contacted
every 2 weeks via a mobile phone text message with the
request to report body weight and encouragement to
continue the program.
A dietitian performed the dietary modification coun-
seling to reduce dietary intake by 500 kcal/day (2 092 kJ/
day) with a nutrient composition according to the Nor-
dic Nutrition Recommendations [11]. The support to
change eating habits consisted of a stepwise plan with
practical changes in diet and estimates of their potential
effects on weight loss. The plan consisted of four steps:
limit sweets, snacks, desserts, sugar-swetened beverages,
etc., to 100 g/week, select foods with low fat and sugar
content, cover half of their plate with vegetables at lunch
and dinner, and reduce portion sizes. The women were
provided with a diet plan booklet with a checklist of ac-
complishment steps for each week, and an electronic
body scale for weighing themselves 3 times/week. They
were advised to implement one step at a time, and to
aim for a rate of 0.5-1.0 kg weight loss per week. Coun-
seling was provided at the research clinic and in follow-
up counseling in the women’s homes.
Control group
Women in the control group received usual care. They
were asked not to engage in other lifestyle modification
programs during the first 12 weeks of the study.
Cost effectiveness measurements
Costs were during 2012-2013 calculated based on trial
staff ’s estimated time consumption per participant. In the
calculation, national mean wages [12] and actual expenses
of equipment were used. Costs for care center rent and
overheads were also estimated. Costs related to the devel-
opment of the methodology and costs for actitivities en-
tirely related to research methodology were not included
in the estimates. Quality of life (QOL) was measured by
EQ-5D-3 L in combination with preference scores from a
time trade-off measurement in a British population [13,14]
as well as by SF-6D (based on SF-36) in combination with
preference scores measured with the standard gamble
method from a British population [15,16].
All costs were transformed from Swedish currency
(SEK) to American dollars (USD) using the exchange rate
1 USD = 7.0 SEK. Costs were recalculated to year 2012
Screening and baseline 
measurements (n=76)
Randomization (n=68)
Assigned to intervention group 
(n=33)
1 y measurements (n=29)
12 wk measurements (n=31)
Assigned to control group 
(n=35)
12 wk measurements (n=31)
1 y measurements (n=28)
Not eligible (n=5)
Withdrew (n=3)
Figure 1 Screening, randomization, and follow-up in the LEVA study.
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effects and changes in costs were assumed to change
linearly between measurement times, and were discounted
at 3% per year.
Health economic analysis method
The analysis in this study was a cost-utility analysis with
a societal perspective, using gained quality adjusted life
years (QALY) as the measure of health effects [18].
Cost-effectiveness ratios were based on the changes in
QOL and costs for the intervention group as compared
with the control group. Due to all women being on
maternal leave, no loss of productivity was incurred and
consequently not included in any analyses. Gained
QALY was calculated from the difference in QOL be-
tween the intervention and control groups at the
follow-up times. Linearly effects were assumed and cal-
culated as follows: For example, if QOL had increased
0.04 more at 3 months and 0.12 more at 1 year in the
intervention group than in the control group, the mean
change during the first three months would be 0.02
(0.00 + 0.04/2) and during the following nine months
0.08 (0.04 + 0.12/2). Gained QALY for this year would
be 0.065 ((0.02×3/12) + (0.08×9/12)).
The timeframe of the analysis is lifelong, but in the
base case no effect of the intervention is assumed to re-
main after 1 year follow-up. The change from baseline
to 1 year follow-up seems to have been progressive and
is therefore unlikley to suddenly change. Hence, a mean
of 1 year remaining effect may be more realistic than no
effect after 1-year follow-up. In a sensitivity analysis,two alternative scenarios were calculated; all effects are
lost 1 year and 3 years after the follow-up, respectively.
Alternative cost effectiveness ratios were also calculated
with reduced (50%) effect on QALY and doubled costs
of the intervention.
Cost-effectiveness is often calculated from the mean
difference in costs and effects, and is calculated between
two or more possible treatment options. The use of
mean values for cost-effectiveness ratios is associated
with uncertainty. In the current analysis, this uncer-
tainty was handled with the Net Monetary Benefit
method [19,20]. The method is based on replacing
health effects (QALYs), on an individual level, with the
amount of money decision makers are willing to pay
for a gained QALY. When all data are expressed in
money, it is possible to calculate a confidence interval
for cost-effectiveness and the likelihood that an inter-
vention is cost-effective in relation to a competing
intervention.
A scatter plot of 5 000 bootstrapped incremental cost-
effectiveness ratios was created by repeatedly drawing a
random sample with replacement using parameters esti-
mated from the study. Individual values were used for
gained QALY, and mean values were used for costs re-
lated to the intervention (diet and/or physical exercise)
that participants received. In such a way, the likelihood
that the intervention was cost-effective using several
thresholds of willingness to pay for a QALY was calcu-
lated. Further, mean Net Monetary Benefit and confi-
dence intervals of Net Monetary Benefit were estimated
for these threshold values.
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Data were analyzed according to the intention-to-treat
principle, with participants remaining in their original
study groups. If data were missing, the last-observation-
carried-forward method was used [21-23]. Participants
who did not take part in a follow-up were accordingly
assumed to have unchanged values. Differences between
groups were evaluated using t-test for normally distrib-
uted numerical variables. P-values <0.05 were regarded
as statistically significant differences.
Results
Of 68 subjects included in the study, 57 completed the
1-year follow-up (Figure 1).
Costs
Costs were 302.5 USD higher per participant for the
women in the intervention group compared to the women
in the control group (Table 1).
Health effect
After 1 year, the intervention group had increased their
QOL in addition to that of the control group with 0.053
(P = 0.10) (based on EQ-5D-3 L) and 0.044 (P = 0.03)
(based on SF-6D) (Table 2). Based on the above data,
gained QALY of the intervention group, in addition to that
of the control group during the follow-up year, was 0.035
(P = 0.19) using the EQ-5D-3 L, and 0.031 (P = 0.07) using
the SF-6D (Table 3).
Cost-effectiveness
Costs were 8 643 USD (based on EQ-5D-3 L) and 9 758
USD (based on SF-6D) per gained QALY considering the
follow-up year. With assumptions of 1 year remaining
effect beyond the 1-year follow-up, the cost-effectiveness
ratios were 3 477 and 4 088 USD per gained QALY, re-
spectively. With the assumption of a 3-years remaining
effect, the ratios were 1 644 and 1 939 USD per gained
QALY, respectively.Table 1 Costs (USD) per participant in the LEVA diet weight l
Type of costs Intervention gr
Start of intervention, 1 h 50 min dietitian 61.0
1 home visit, time and travel 74.4
Telephone costs, time and telephone fee 23.0
Participants’ travel expenses 108.9
Equipment 78.1
Costs of physical exercise interventiona 141.1
Sum of direct costs 486.5
Overhead, administration and local costs, 20% 97.3
Sum of total costs per participant 583.8
aIncluding the same kind of costs and the same running time as in the diet interveNet Monetary Benefits were higher for the intervention
group than for the control group in all calculations, inde-
pendent of time of remaining effect, value of a QALY and
choice of QOL instrument. Net Moneary Benefts were sig-
nificantly higher for the intervention group compared to
those of the control group using calculations of QALYs
based on SF-6D, a willingness to pay for a QALY of at
least 100 000 USD, and with an assumption of remaining
effect of at least 1 year. With the assumption of 3-year
remaining effect, there were significant differences in Net
Monetary Benefits between the groups also, with willing-
ness to pay for a QALY set to 50 000 USD (Table 4).
The likelihood of cost-effectiveness was 0.52 – 0.95
considering follow-up year, when willingness to pay for a
QALY was set to 10 000 – 100 000 USD (Figure 2 and
Table 5).
Acceptable cost-effectiveness ratios (around 40 000
USD/QALY) can be obtained also when gained QALY is
a fifth of the base case. With halved gained QALY or
with doubled cost, the cost-effectiveness ratios are still
low (less than 20 000 USD/QALY).
Discussion
Principal findings
In this dietary weight loss intervention among overweight
and obese lactating women, costs per gained QALY were
8 643 – 9 758 USD based on an assumption of no
remaining effect after the follow-up year. With a willing-
ness to pay of 50 000 USD for a QALY, the likelihood
for cost-effectiveness was 87 – 93%.
Long-term effects of weight loss programs have gener-
ally not been very successful, with half of the weight lost
regained again during the first year of follow-up [7]. In
contrast, the women in this study actually continued to
lose weight between end of the 12-week intervention
and the follow-up 9 months later. The reasons for the
success of this program are many, including motivation
to lose weight after pregnancy, motivation because of
parental responsibility, the possibility of implementingoss intervention trial










ntion, but performed by a physiotherapeut.
Table 2 Treatment effect on QOL based on EQ-5D-3 L and SF-6D in the LEVA trial
Baseline 3 months 1 year
QOLa P-value QOL change from baseline P-value QOL change from baseline P-value
Based on EQ-5D-3 L
Intervention group 0.889 +0.013 0.60 +0.022 0.37
Control group 0.880 -0.017 0.56 -0.031 0.15
Difference intervention-control +0.019 0.48 +0.030 0.43 +0.053 0.10
Based on SF-6D
Intervention group 0.706 +0.048 <0.01 +0.047 <0.01
Control group 0.702 +0.020 0.09 +0.003 0.83
Difference intervention-control +0.004 0.82 +0.028 0.17 +0.044 0.03
aQOL, Quality of Life.
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execution of the behavior modification program itself [10].
The perceived increase in quality of life in the diet treat-
ment group may be related to the weight reduction per se,
but also to the feeling of being able to control one’s life-
style and weight, and to make proper choices regarding
the diet for themselves and their families.
The approach in this analysis was to calculate the treat-
ment effect as changes in QOL. Additionally, there may be
preventive effects against diseases such as type 2 diabetes,
heart diseases and osteoarthritis, with possibilities for even
better cost-effectiveness ratios. Thus, our results likely
underestimate the full cost-effectiveness of the intervention.
Although not all beneficial effects are taken into ac-
count, the cost-effectiveness ratio in this study is well
below usually accepted cost-effectiveness ratios. There is
no formal level of acceptable cost of a QALY in the
USA, although 50 000 USD and 100 000 USD are often
used [24]. There is also no official level in Great Britain,
but The British National Institute for Clinical Excellence
applies 20 000 – 30 000 GBP (around 32 000 – 50 000
USD) as acceptable costs, and in Sweden a threshold of
500 000 SEK (37 500 USD) has importance in decisions
about subsidized medicine [25].
Results in relation to other studies
To our knowledge, this is the first analysis of cost-
effectiveness of a certain diet intervention trial among
overweight or obese women in the postpartum period.Table 3 Gained QALY for Intervention group beyond that of c
Assumption of remaining time of effect Based o
QALYb
Follow-up 0.035
Follow-up + 1 year 0.087
Follow-up + 3 years 0.184
aCalculated during the 1 year follow-up, and with assumption of remaining effect in
per year.
bQALY, Quality-adjusted life years.However, some analyses of interest have been published in
similar fields. In 2011, a model analysis was made estimat-
ing cost-effectiveness of weight management interventions
following pregnancy [26]. Based on best available data, the
preventive effect and the cost-effectiveness were estimated
based on changes in weight and BMI after 6 months. Cost
per QALY was estimated to 44 144 GBP with a time hori-
zon of 15 years. Consequently, acceptable cost effective-
ness ratios can be seen in a short-term treatment
perspective as well as in a long-term preventive perspec-
tive. Further, cost-effectiveness has been calculated for
The Counterweight programme in the UK [27]. This was
a family practice-based and theory-based intervention
among overweight and obese adults. An economic model
study estimated preventive health gains based on changes
in BMI after 1 year; the cost-effectiveness ratio was accept-
able despite conservative assumptions. Additionally, Roux
has shown benefits of weight loss among overweight and
obese adults in a lifetime model with the potential of ac-
ceptable cost-effectiveness ratio [28]. Dalziel and collea-
geus have performed model analysis of several nutrition
interventions among overweight and obese adults showing
acceptable cost-effectiveness ratios of well-performed in-
terventions [29]. Loveman and colleagues in a literature
review in 2011 concluded that some evidence exist of
cost-effective weight management programs, but caution
is required due to analysis methodology [30]. From these
data, it is clear that nutrition and weight management in-
terventions among overweight and obese adults have aontrol group in the LEVA triala





1 year and 3 years. Effects after follow-up years are discounted with 3%
Table 4 Net monetary benefit for Intervention group compared to control group in the LEVA triala
QALYb = 10 000 USD QALY = 50 000 USD QALY = 100 000 USD
EQ-5D-3 L SF-6D EQ-5D-3 L SF-6D EQ-5D-3 L SF-6D
Follow-up 46.3 5.4 1441.6 1237.0 3185.7 2776.6
(-477.4–582.1) (-324.5–344.0) (-1137.4–4067.4) (-398.4–2867.9) (-1961.7–8426.6) (-492.2–6030.0)
Follow-up + 1 year 559.9 432.9 4009.7 3374.4 8321.8 7051.3
(-483.9–1627.1)c (-268.5–1135.6) (-1180.8–9268.4) (-106.0–6827.5) (-2085.7–18833.4) (100.2–13953.2)
Follow-up + 3 years 1542.6 1251.2 8923.2 7466.1 18148.9 15234.8
(-609.2–3698.0) (-173.2–2664.1) (-1774.5–19682.4) (367.5-14559.2) (-3235.4–39619.4) (1030.6–29422.1)
aUsing 10 000 USD, 50 000 USD and 100 000 USD as value of a QALY, for the 1 year follow-up and with 1 year and 3 years remaining effect, respectively.
bQALY, Quality-adjusted life years.
c95% Confidence Interval.
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weight loss is sustained. However, all model analyses de-
scribed above are based on assumptions, and not on em-
pirical data, of future weight development.
Strengths and weaknesses of the current study
Health economic analyses are often used as a basis for
decisions on whether a method should become clinical
standard or not. Hence, valid and reliable results are cru-
cial. This requires analyses based on empirical data
throughout the follow-up period, as was done in our case.
Here, we present results on acceptable cost-effectiveness,
which should be sufficient for making decisions on
whether the method should be used as clinical standard or
not. In addition, a preventive effect can be calculated from
measured changes in lifestyle or medical risk markers
among participants, in combination with epidemiological
data on relationships between changes in these lifestyle
factors and risk of diseases or premature death. Hence, the
results presented here may underestimate the total ex-
pected health gains from the intervention.
Of particular importance for determining the high qual-
ity of these analyses is our measurement of QOL. Two in-
struments were used, EQ-5D-3 L and SF-6D. EQ-5D-3 L is
the most frequently used instrument in cost-effectivenessFigure 2 Cost-effectiveness acceptability curve of the base case
(the follow-up year).analyses, at least in Europe. However, this instrument may
have ceiling-effect problems in such a young and healthy
group of participants as ours [31]. SF-6D, based on SF-36,
is more recently developed. It is better able to capture
QOL in our segment of young and healthy participants,
and better able to measure changes because it provides
more alternatives to choose from when answering (e.g.,
18 000 compared to 243 for EQ-5D-3 L). We think that
the validity of our results are enhanced by the fact that the
two calculations show similar results.
No measurements were made of participants’ costs for
food and time spent cooking. Some studies have shown a
healthy diet to be more costly while other studies deem
this not to be the case [32,33]. A study from Sweden
showed that adhering to a diet similar to the advice in this
study is more expensive than adhering to a traditional diet,
when differences in energy intake were discounted [33].
However, as the diet led to a lower energy intake there
were no significant differences in actual costs between di-
ets. Furthermore, this study took no measurements of
health care utilization. However, any such changes may
not have been possible to capture with precision due to
low health care utilization in general.
The study was, in the original design, performed as a
study with four study groups that also included physicalTable 5 Probability of cost-effectiveness of the LEVA trial
using EQ-5D-3 L and SF-6D to calculate QALYa
Willingness to pay for a QALYb
10 000 USD 50 000 USD 100 000 USD
EQ-5D, follow-up 0.57 0.87 0.89
SF-6D, follow-up 0.52 0.93 0.95
EQ-5D, follow-up + 1 year 0.85 0.93 0.94
SF-6D, follow-up + 1 year 0.89 0.97 0.98
EQ-5D, follow-up + 3 years 0.92 0.95 0.95
SF-6D, follow-up + 3 years 0.96 0.98 0.98
aUsing 10 000, 50 000 and 100 000 USD as value of willingness to pay for a
QALY, for the 1 year follow-up and with 1 year and 3 years remaining effect.
bQALY, Quality-adjusted life years.
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with diet intervention. The physical activity intervention
was low targeted with a goal of 8 000 steps a day (which
most of the participants reached) in the intervention
group as well as in the control group. Hence, the phys-
ical activity intervention had no detectable impact on
physical activity levels, energy expenditure, body weight
or body composition.
Two aspects will have a major impact on the cost-
effectiveness: the amount of increase in QOL and how
long the increase continues. We think our analyses have
handled these aspects as thoroughly as possible. For even
more secure results, larger studies with longer follow-up
periods are needed. However, to date, our study has the
longest follow-up available.
Conclusion
According to this study, it may be cost-effective to pro-
mote weight loss by dietary changes among lactating over-
weight and obese women. Maternity leave usually entails
changes in every day life and this period provides a win-
dow of opportunity to implement healthy and sustainable
eating habits. Such programs could be offered within or-
dinary health care.
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